期刊
FRONTIERS IN PHARMACOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.720619
关键词
melanoma; vemurafenib resistance; eIF3a; ERK
资金
- National Key Research and Development Program of China [2016YFC1306900]
- National Natural Science Foundation of China [81874327]
- Key Research and Development Program of Hunan Province [2019SK2251]
- Innovation and Research Project of Development and Reform Committee of Hunan Province [2019-875]
- Project Program of National Clinical Research Center for Geriatric Disorders [2020LNJJ02]
- Science and Technology Program of Changsha [kh2003010]
In this study, the researchers found that eIF3a plays a crucial role in vemurafenib resistance by controlling ERK activity and influencing the sensitivity of melanoma cells to BRAF inhibitors. Furthermore, a positive correlation between eIF3a and PPP2R1B expression was observed in tumor samples, suggesting a potential new strategy for predicting vemurafenib responses in clinical treatment.
Vemurafenib, a BRAF V600E inhibitor, provides therapeutic benefits for patients with melanoma, but the frequent emergence of drug resistance remains a challenge. An understanding of the mechanisms underlying vemurafenib resistance may generate novel therapeutic strategies for patients with melanoma. Here, we showed that eIF3a, a translational regulatory protein, was an important mediator involved in vemurafenib resistance. eIF3a was expressed at significantly lower levels in vemurafenib-resistant A375 melanoma cells (A375R) than in parental A375 cells. Overexpression of eIF3a enhanced the sensitivity to BRAF inhibitors by reducing p-ERK levels. Furthermore, eIF3a controlled ERK activity by regulating the expression of the phosphatase PPP2R1B via a translation mechanism, thus determining the sensitivity of melanoma cells to vemurafenib. In addition, a positive correlation between eIF3a and PPP2R1B expression was also observed in tumor samples from the Human Protein Atlas and TCGA databases. In conclusion, our studies reveal a previously unknown molecular mechanism of BRAF inhibitor resistance, which may provide a new strategy for predicting vemurafenib responses in clinical treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据